A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.

Nazha, Aziz; Hu, Zhen-Huan; Wang, Tao; Lindsley, R Coleman; Abdel-Azim, Hisham; Aljurf, Mahmoud; Bacher, Ulrike; Bashey, Asad; Cahn, Jean-Yves; Cerny, Jan; Copelan, Edward; DeFilipp, Zachariah; Diaz, Miguel Angel; Farhadfar, Nosha; Gadalla, Shahinaz M; Gale, Robert Peter; George, Biju; Gergis, Usama; Grunwald, Michael R; Hamilton, Betty; ... (2020). A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of blood and marrow transplantation, 26(11), pp. 2139-2146. Elsevier 10.1016/j.bbmt.2020.08.003

[img] Text
A Personalized Prediction .pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Allogeneic hematopoietic stem cell transplantation (HCT) remains the only potentially curative option for myelodysplastic syndromes (MDS). Mortality after HCT is high, with deaths related to relapse or transplant-related complications. Thus, identifying patients who may or may not benefit from HCT is clinically important. We identified 1514 patients with MDS enrolled in the Center for International Blood and Marrow Transplant Research Registry and had their peripheral blood samples sequenced for the presence of 129 commonly mutated genes in myeloid malignancies. A random survival forest algorithm was used to build the model, and the accuracy of the proposed model was assessed by concordance index. The median age of the entire cohort was 59 years. The most commonly mutated genes were ASXL1(20%), TP53 (19%), DNMT3A (15%), and TET2 (12%). The algorithm identified the following variables prior to HCT that impacted overall survival: age, TP53 mutations, absolute neutrophils count, cytogenetics per International Prognostic Scoring System-Revised, Karnofsky performance status, conditioning regimen, donor age, WBC count, hemoglobin, diagnosis of therapy-related MDS, peripheral blast percentage, mutations in RAS pathway, JAK2 mutation, number of mutations/sample, ZRSR2, and CUX1 mutations. Different variables impacted the risk of relapse post-transplant. The new model can provide survival probability at different time points that are specific (personalized) for a given patient based on the clinical and mutational variables that are listed above. The outcomes' probability at different time points may aid physicians and patients in their decision regarding HCT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1083-8791

Publisher:

Elsevier

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

21 Sep 2020 15:33

Last Modified:

03 Nov 2020 01:39

Publisher DOI:

10.1016/j.bbmt.2020.08.003

PubMed ID:

32781289

Uncontrolled Keywords:

Genomic biomarkers MDS Mutations

BORIS DOI:

10.7892/boris.146348

URI:

https://boris.unibe.ch/id/eprint/146348

Actions (login required)

Edit item Edit item
Provide Feedback